Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis

Lung

Volumn 192, Issue 1, 2014, Pages 205-210

  Liu, Yuag Meng ^a,b   Cheng, Yu Jen ^b   Li, Yu Lin ^b   Liu, Chun Eng ^b   Hsu, Wu Huei ^c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antitubercular agents; Drug induced liver injury; Hepatitis B virus; Hepatitis C virus

Indexed keywords

AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; COINFECTION; DRUG-INDUCED LIVER INJURY; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TAIWAN; TERTIARY CARE CENTERS; TIME FACTORS; TUBERCULOSIS;

EID: 84894065602     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-013-9535-8     Document Type: Article

References (30)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC (1999) Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282(7):677-686
2. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA (2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 167(4):603-662. doi: 10.1164/rccm.167.4.603
3. Liao CM, Hsieh NH, Huang TL, Cheng YH, Lin YJ, Chio CP, Chen SC, Ling MP (2012) Assessing trends and predictors of tuberculosis in Taiwan. BMC Public Health 12:29. doi: 10.1186/1471-2458-12-29
4. Chen CJ, Yang HI (2011) Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 26(4):628-638. doi: 10.1111/j.1440-1746.2011.06695.x
5. Lee MH, Yang HI, Jen CL, Lu SN, Yeh SH, Liu CJ, You SL, Sun CA, Wang LY, Chen WJ, Chen CJ (2011) Community and personal risk factors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan in 1991-1992. Gut 60(5):688-694. doi: 10.1136/gut.2010.220889
6. Døssing M, Wilcke JT, Askgaard DS, Nybo B (1996) Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 77(4):335-340
7. Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK (1996) Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 51(2):132-136
8. Schaberg T, Rebhan K, Lode H (1996) Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 9(10):2026-2030
9. Amarapurkar DN, Prabhudesai PP, Kalro RH, Desai HG (1993) Antituberculosis drug-induced hepatitis and HBsAg carriers. Tuber Lung Dis 74(3):215-216
10. Hwang SJ, Wu JC, Lee CN, Yen FS, Lu CL, Lin TP, Lee SD (1997) A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 12(1):87-91
11. Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, Kwon OJ (2005) Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 127(4):1304-1311. doi: 10.1378/chest.127.4. 1304
12. Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, Tam CM, Leung CC, Lai CL (2000) Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 31(1):201-206. doi: 10.1002/hep.510310129
13. Wu JC, Lee SD, Yeh PF, Chan CY, Wang YJ, Huang YS, Tsai YT, Lee PY, Ting LP, Lo KJ (1990) Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 98(2):502-504
14. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE (1998) Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 157(6 Pt 1):1871-1876
15. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D (2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167(11):1472-1477. doi: 10.1164/rccm.200206-626OC
16. Yew WW, Leung CC (2006) Antituberculosis drugs and hepatotoxicity. Respirology 11(6):699-707. doi: 10.1111/j.1440-1843.2006.00941.x
17. Joint Tuberculosis Committee of the British Thoracic Society (1998) Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 53(7):536-548
18. Turktas H, Unsal M, Tulek N, Oruc O (1994) Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis. Tuber Lung Dis 75(1):58-60. doi: 10.1016/0962-8479(94)90104-X
19. Tost JR, Vidal R, Cayla J, Diaz-Cabanela D, Jimenez A, Broquetas JM (2005) Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis 9(5):534-540
20. Whittington RM (1991) Fatal hepatotoxicity of anti-tubercular chemotherapy. Lancet 338(8774):1083-1084
21. Devarbhavi H, Dierkhising R, Kremers WK (2010) Antituberculosis therapy drug-induced liver injury and acute liver failure. Hepatology 52(2):798-799; author reply 799-800. doi: 10.1002/hep.23805
22. Devarbhavi H, Singh R, Patil M, Sheth K, Adarsh CK, Balaraju G (2013) Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol 28(1):161-167. doi: 10.1111/j.1440-1746.2012.07279.x
23. Kumar R, Bhatia V, Khanal S, Sreenivas V, Gupta SD, Panda SK, Acharya SK (2010) Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology 51(5):1665-1674. doi: 10.1002/hep.23534
24. Wang JY, Liu CH, Hu FC, Chang HC, Liu JL, Chen JM, Yu CJ, Lee LN, Kao JH, Yang PC (2011) Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect 62(6):448-455. doi: 10.1016/j.jinf.2011.04.005
25. Chien JY, Huang RM, Wang JY, Ruan SY, Chien YJ, Yu CJ, Yang PC (2010) Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment. Int J Tuberc Lung Dis 14(5):616-621
26. Girling DJ (1982) Adverse effects of antituberculosis drugs. Drugs 23(1-2):56-74
27. Sun HY, Chen YJ, Gau CS, Chang SC, Luh KT (2009) A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature. J Formos Med Assoc 108(2):102-111
28. Liu Q, Garner P, Wang Y, Huang B, Smith H (2008) Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies. BMC Public Health 8:365. doi: 10.1186/1471-2458-8-365
29. Stickel F, Schuppan D (2007) Herbal medicine in the treatment of liver diseases. Dig Liver Dis 39(4):293-304. doi: 10.1016/j.dld.2006.11.004
30. Lee SD, Wang YJ, Lu RH, Chan CY, Lo KJ, Moeckli R (1994) Seroprevalence of antibody to hepatitis E virus among Chinese subjects in Taiwan. Hepatology 19(4):866-870